2019 - 2020

Categories:History
Author:
Origin:
Time of issue:2020-03-09
Views:0

(Summary description)
◆ Completing thebioequivalency evaluationof the first generic drug for rare diseases.
◆ Completing Phase I clinical trial of a new hypoglycemic drug.
◆ Raising 150 million yuaninSeries A+ round financing.

2019 - 2020

(Summary description)
◆ Completing thebioequivalency evaluationof the first generic drug for rare diseases.
◆ Completing Phase I clinical trial of a new hypoglycemic drug.
◆ Raising 150 million yuaninSeries A+ round financing.

Categories:History
Author:
Origin:
Time of issue:2020-03-09
Views:0

A heavy load and a long way to go

Previous: 2020 - 2021

Next: 2018 - 2019

Previous: 2020 - 2021

Next: 2018 - 2019

Media Attention | Yu Qiang, an "unsmart" entrepreneur, and his new diabetes drug Sengliptin

Qiang Yu, the founder and CEO of CGeneTech, a doctor of chemistry from Peking University, founded a biotechnology company in the United States at the beginning of this century, and later returned to China to found CGeneTech and developed a new type 2 diabetes drug, a new generation of DPP-4 inhibitor senpaglitin, which has now been approved for marketing.

2025-04-16

Media Attention | Professor Su Qing: Based on the status quo and taking innovation as the wing, sengliptin opens a new chapter in the treatment of DPP-4 inhibitors

In recent years, the prevalence of diabetes in China has continued to rise, but the control rate is still at a low level, and more effective prevention and control measures and optimized treatment options are urgently needed. In this context, the new generation of DPP-4 inhibitor senpaliptin has been approved for marketing in China, providing a new option for the treatment of T2DM. In order to have a deeper understanding of the current status of diabetes mellitus in China, as well as the important value of DPP-4 inhibitors in hypoglycemic therapy, especially the drug characteristics and hypoglycemic efficacy of the new generation of DPP-4 inhibitor senpaglitin, we specially invited Professor Su Qing from Xinhua Hospital affiliated to Shanghai Jiao Tong University School of Medicine to conduct an in-depth interview to share his professional insights and valuable experience.

2025-04-15